Chris Cabell, M.D.

Chris Cabell, M.D.

President and Head of Research and DevelopmentatInhibikase Therapeutics· In the 2025 proxy

Pay in FY2025Inhibikase Therapeutics stock -36.9% the same year

Chris Cabell, M.D. was paid $7.5M in FY2025 (Dec). Inhibikase Therapeutics stock fell 36.9% that year.

Pay$100 in the stock at the end of FY24 → $63
Pay is from the Summary Compensation Table of each Inhibikase Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Inhibikase TherapeuticsPublic company · 1 yr
    • President and Head of Research and Development2025 – Present · 1 yrStock in role -45%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?